NanoSyrinx featured in Nature Biopharma Dealmakers
NanoSyrinx is delighted to have been featured in Nature’s Biopharma Dealmakers in an in-depth article exploring how the company is engineering bacterial nanomachines into a new therapeutic modality for targeted intracellular protein delivery.
The article highlights NanoSyrinx’s progress in tackling the longstanding challenge that >80% of intracellular targets remain undruggable, our platform’s ability to deliver diverse therapeutic proteins directly into the cytosol of target cells, and our hybrid strategy of advancing internal programmes while building collaborations with pharma partners to unlock previously inaccessible biology across multiple therapeutic areas.
The full article can be read at the link below.
